StockNews.AI
LLY
StockNews.AI
174 days

Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion

1. Eli Lilly plans to build four new U.S. manufacturing sites. 2. This investment exceeds $50 billion since 2020, creating 13,000 jobs. 3. New sites will enhance supply chain and support various therapeutic areas. 4. Lilly aims for increased exports and domestic production of pharmaceuticals. 5. The move could stimulate economic growth and workforce development.

10m saved
Insight
Article

FAQ

Why Very Bullish?

Lilly's significant investment demonstrates strong confidence in its future growth, which historically boosts stock prices. Similar past expansions have typically led to positive market reactions, reflecting investor optimism about long-term growth.

How important is it?

The article outlines a transformative investment strategy that could drastically improve Lilly's market position and operational capabilities, making it highly relevant to investors and stakeholders.

Why Long Term?

The effects of this investment, particularly in job creation and operational capacity, will manifest over multiple years as facilities are completed and operational. Lilly's long-term commitment to infrastructure indicates sustained growth potential.

Related Companies

AMGNPFEJNJ
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America The company's plans represent the largest pharmaceutical manufacturing investment in U.S. history , /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced at a press conference in Washington, D.C., plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States. This brings the company's total U.S. capital expansion commitments to more than $50 billion since 2020. Three of the future U.S. sites announced today will focus on manufacturing active pharmaceutical ingredients (API), reshoring critical capabilities of small molecule chemical synthesis and further strengthening Lilly's supply chain. The fourth location will extend the company's global parenteral manufacturing network for future injectable therapies. "Lilly's optimism about the potential of our pipeline across therapeutic areas – cardiometabolic health, oncology, immunology and neuroscience – drives our unprecedented commitment to our domestic manufacturing build-out. Our confidence positions us to help reinvigorate domestic manufacturing, which will benefit hard-working American families and increase exports of medicines made in the U.S.A.," said David A. Ricks, Lilly chair and CEO. "This bold move reflects our commitment to stay ahead of anticipated demand for safe, high-quality, FDA-approved medicines of the future." At these four new sites, Lilly expects to create more than 3,000 jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians. Additionally, the company anticipates that it could create nearly 10,000 construction jobs during the development of the sites. "To deliver on our big bets on next-generation modalities like small molecules, biologics and nucleic acid therapies, Lilly is investing in the state-of-the-art manufacturing infrastructure needed to deliver tomorrow's safe and reliable medicines," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. "We are not just building facilities. We are creating a future where American innovation leads the world in pharmaceutical manufacturing, requiring a highly skilled workforce prepared to shape the future of health care. This is a significant step for our company, our communities and the patients we serve." Expected additional economic benefits of these new sites to the selected communities include increased local spending, tax revenue, economic diversification, improved infrastructure, population growth, and training and development opportunities. Ricks added, "The Tax Cuts and Jobs Act legislation passed in 2017 during President Trump's first term in office has been foundational to Lilly's domestic manufacturing investments, and it is essential that these policies are extended this year. We believe that our investments in America and upskilling our nation's workforce will spark a significant ripple effect. For every job we create, many more will be generated, positively impacting the communities that host our innovative new sites." The company's previous total domestic capital expansion commitments from 2020 to 2024 totaled $23 billion and represented in today's $50 billion announcement, included: New sites in Research Triangle Park and Concord, North Carolina New sites at the LEAP Innovation District in Lebanon, Indiana Expansions and updates to several different manufacturing facilities in Indianapolis Development of the new Lilly Medicine Foundry in Lebanon, Indiana Acquisition and expansion of Lilly's manufacturing site in Kenosha County, Wisconsin State submissionsThe company is currently in negotiations with several states and welcomes additional interest by March 12, 2025. Please visit www.lilly.com/manufacturing-2025 for more information, including how to respond and submit interest online. Lilly expects to announce all four future site locations in 2025 and anticipates facilities will begin making medicines for patients within five years. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. C-LLY Trademarks and Trade NamesAll trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) including about planned capital investments in new manufacturing capacity, production of medicines, hiring and related initiatives and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in the manufacturing process, development and commercialization of pharmaceutical products any of which could impact the overall commercial success of our products, and as related to cost, completion timing, expected capacity, personnel, and other factors which could impact expected benefits of the capacity expansion and related initiatives. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. Additional Quote Options for Media Use U.S. Senator Jim Banks: "I couldn't be prouder that Lilly is expanding facilities in the U.S. These new investments will create good jobs and make our supply chains more secure." U.S. Senator Todd Young: "Lilly has long been a driver of economic growth and innovation in Indiana, and we are grateful for this further investment in America and our workers. Lilly is continuously striving to improve the lives of people everywhere, and today we celebrate the transformative impact of this announcement." SOURCE Eli Lilly and Company WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News